Go Pro
→ A weekly dividend fund holding Nvidia and Palantir (From Investors Alley) (Ad)tc pixel Free MCTA Stock Alerts

Charming Medical (MCTA) Financials

Charming Medical logo
$29.36 -0.01 (-0.02%)
As of 08/10/2026
Compare
Annual Income Statements for Charming Medical

Annual Income Statements for Charming Medical

This table shows Charming Medical's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2024 2025 2026
Period end date 3/31/2024 3/31/2025 3/31/2026
Net Income / (Loss) Attributable to Common Shareholders		 0.78 1.20 -0.02
Consolidated Net Income / (Loss)		 0.82 1.20 -0.02
Net Income / (Loss) Continuing Operations		 0.82 1.20 -0.02
Total Pre-Tax Income 		1.00 1.44 0.13
Total Operating Income		 1.01 1.39 -0.03
Total Gross Profit		 6.00 6.21 4.77
Total Revenue		 6.02 6.22 4.81
Operating Revenue		 6.02 6.22 4.81
Total Cost of Revenue		 0.01 0.02 0.04
Operating Cost of Revenue		 0.01 0.02 0.04
Total Operating Expenses		 5.00 4.82 4.80
Selling, General & Admin Expense		 0.64 0.61 1.33
Marketing Expense		 0.86 1.00 0.80
Depreciation Expense		 0.39 0.26 0.22
Other Operating Expenses / (Income)		 3.10 2.95 2.45
Total Other Income / (Expense), net		 -0.01 0.05 0.16
Interest Expense		 0.03 0.02 0.02
Interest & Investment Income		 0.02 0.06 0.07
Other Income / (Expense), net		 0.00 0.00 0.11
Income Tax Expense		 0.18 0.24 0.16
Net Income / (Loss) Attributable to Noncontrolling Interest		 0.04 0.00 0.00
Basic Earnings per Share		 $0.05 $0.08 $0.00
Weighted Average Basic Shares Outstanding		 15.34M 15.34M 16.15M
Diluted Earnings per Share		 $0.05 $0.08 $0.00
Weighted Average Diluted Shares Outstanding		 15.34M 15.34M 16.15M
Weighted Average Basic & Diluted Shares Outstanding		 - - 17.18M

Quarterly Income Statements for Charming Medical

No quarterly income statements for Charming Medical are available.

Annual Cash Flow Statements for Charming Medical

This table details how cash moves in and out of Charming Medical's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2024 2025 2026
Period end date 3/31/2024 3/31/2025 3/31/2026
Net Change in Cash & Equivalents		 0.18 -1.28 3.90
Net Cash From Operating Activities		 0.30 0.43 -1.22
Net Cash From Continuing Operating Activities		 0.30 0.43 -1.22
Net Income / (Loss) Continuing Operations		 0.82 1.20 -0.02
Consolidated Net Income / (Loss)		 0.82 1.20 -0.02
Depreciation Expense		 0.39 0.26 0.22
Non-Cash Adjustments To Reconcile Net Income		 -0.04 -0.01 -0.06
Changes in Operating Assets and Liabilities, net		 -0.88 -1.03 -1.35
Net Cash From Investing Activities		 -0.21 -2.23 -0.18
Net Cash From Continuing Investing Activities		 -0.21 -2.23 -0.18
Purchase of Property, Plant & Equipment		 -0.21 -0.29 -0.34
Purchase of Investments		 0.00 -0.50 -0.01
Sale of Property, Plant & Equipment		 0.00 0.00 0.03
Other Investing Activities, net		 0.00 -1.44 0.14
Net Cash From Financing Activities		 0.10 0.52 5.29
Net Cash From Continuing Financing Activities		 0.10 0.52 5.29
Repayment of Debt		 -0.15 -0.13 -0.13
Repurchase of Preferred Equity		 -0.03 -0.55 -1.18
Issuance of Debt		 0.04 0.21 0.00
Issuance of Common Equity		 0.00 0.00 6.53
Other Financing Activities, net		 0.24 0.99 0.06
Cash Interest Paid		 0.03 0.02 0.02
Cash Interest Received		 0.02 0.06 0.07

Quarterly Cash Flow Statements for Charming Medical

No quarterly cash flow statements for Charming Medical are available.

Annual Balance Sheets for Charming Medical

This table presents Charming Medical's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2025 2026
Period end date 3/31/2025 3/31/2026
Total Assets		 5.36 9.87
Total Current Assets		 3.37 8.17
Cash & Equivalents		 0.82 4.70
Short-Term Investments		 0.50 1.84
Accounts Receivable		 0.40 0.20
Inventories, net		 0.03 0.03
Other Current Assets		 1.62 1.41
Plant, Property, & Equipment, net		 0.50 0.61
Total Noncurrent Assets		 1.49 1.09
Noncurrent Deferred & Refundable Income Taxes		 0.08 0.01
Other Noncurrent Operating Assets		 1.41 1.08
Total Liabilities & Shareholders' Equity		 5.36 9.87
Total Liabilities		 5.31 4.69
Total Current Liabilities		 4.95 4.33
Short-Term Debt		 0.31 0.19
Accounts Payable		 0.25 0.42
Current Deferred & Payable Income Tax Liabilities		 0.22 0.31
Other Current Liabilities		 4.17 3.42
Total Noncurrent Liabilities		 0.36 0.36
Other Noncurrent Operating Liabilities		 0.36 0.36
Commitments & Contingencies		 0.00 0.00
Total Equity & Noncontrolling Interests		 0.05 5.18
Total Preferred & Common Equity		 0.05 5.18
Total Common Equity		 0.05 5.18
Common Stock		 0.31 5.10
Retained Earnings		 0.12 0.10
Accumulated Other Comprehensive Income / (Loss)		 -0.00 -0.01
Other Equity Adjustments		 -0.38 0.00

Quarterly Balance Sheets for Charming Medical

No quarterly balance sheets for Charming Medical are available.

Annual Metrics And Ratios for Charming Medical

This table displays calculated financial ratios and metrics derived from Charming Medical's official financial filings.

Metric 2024 2025 2026
Period end date 3/31/2024 3/31/2025 3/31/2026
DEI Shares Outstanding		 0.00 0.00 17,178,000.00
DEI Adjusted Shares Outstanding		 0.00 0.00 17,178,000.00
DEI Earnings Per Adjusted Shares Outstanding		 0.00 0.00 0.00
Growth Metrics		 - - -
Revenue Growth		 0.00% 3.43% -22.73%
EBITDA Growth		 0.00% 18.09% -82.32%
EBIT Growth		 0.00% 37.81% -94.50%
NOPAT Growth		 0.00% 40.47% -99.57%
Net Income Growth		 0.00% 45.92% -101.89%
EPS Growth		 0.00% 60.00% -100.00%
Operating Cash Flow Growth		 0.00% 44.16% -385.50%
Free Cash Flow Firm Growth		 0.00% 0.00% -89.71%
Invested Capital Growth		 0.00% 0.00% -22.25%
Revenue Q/Q Growth		 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 0.00% 0.00% 0.00%
EBIT Q/Q Growth		 0.00% 0.00% 0.00%
NOPAT Q/Q Growth		 0.00% 0.00% 0.00%
Net Income Q/Q Growth		 0.00% 0.00% 0.00%
EPS Q/Q Growth		 0.00% 0.00% 0.00%
Operating Cash Flow Q/Q Growth		 0.00% 0.00% 0.00%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 0.00%
Invested Capital Q/Q Growth		 0.00% 0.00% 0.00%
Profitability Metrics		 - - -
Gross Margin		 99.81% 99.75% 99.27%
EBITDA Margin		 23.30% 26.61% 6.09%
Operating Margin		 16.77% 22.32% -0.61%
EBIT Margin		 16.79% 22.37% 1.59%
Profit (Net Income) Margin		 13.66% 19.27% -0.47%
Tax Burden Percent		 81.89% 83.55% -16.97%
Interest Burden Percent		 99.35% 103.11% 174.21%
Effective Tax Rate		 18.11% 16.45% 116.97%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00%
Return on Equity (ROE)		 0.00% 2,435.04% -0.87%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% 25.99% 1.01%
Return on Assets (ROA)		 0.00% 22.39% -0.30%
Return on Common Equity (ROCE)		 0.00% 2,435.04% -0.87%
Return on Equity Simple (ROE_SIMPLE)		 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 0.83 1.16 0.00
NOPAT Margin		 13.73% 18.65% 0.10%
Net Nonoperating Expense Percent (NNEP)		 0.00% 7.68% -0.75%
Return On Investment Capital (ROIC_SIMPLE)		 - 319.27% 0.09%
Cost of Revenue to Revenue		 0.19% 0.25% 0.73%
SG&A Expenses to Revenue		 10.67% 9.74% 27.65%
R&D to Revenue		 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 83.04% 77.43% 99.88%
Earnings before Interest and Taxes (EBIT)		 1.01 1.39 0.08
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 1.40 1.66 0.29
Valuation Ratios		 - - -
Price to Book Value (P/BV)		 0.00 129.97 91.51
Price to Tangible Book Value (P/TBV)		 0.00 129.97 91.51
Price to Revenue (P/Rev)		 1.06 1.03 98.61
Price to Earnings (P/E)		 8.23 5.34 0.00
Dividend Yield		 0.00% 0.00% 0.00%
Earnings Yield		 12.15% 18.74% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.87 97.29
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 3.26 1,598.06
Enterprise Value to EBIT (EV/EBIT)		 0.00 3.88 6,105.08
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 4.65 94,277.31
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 12.67 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 2.55 2,147.10
Leverage & Solvency		 - - -
Debt to Equity		 0.00 6.38 0.04
Long-Term Debt to Equity		 0.00 0.00 0.00
Financial Leverage		 0.00 -20.43 -1.41
Leverage Ratio		 0.00 108.76 2.91
Compound Leverage Factor		 0.00 112.14 5.07
Debt to Total Capital		 0.00% 86.45% 3.46%
Short-Term Debt to Total Capital		 0.00% 86.45% 3.46%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00%
Common Equity to Total Capital		 0.00% 13.55% 96.54%
Debt to EBITDA		 0.00 0.19 0.63
Net Debt to EBITDA		 0.00 -0.61 -21.70
Long-Term Debt to EBITDA		 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.27 37.45
Net Debt to NOPAT		 0.00 -0.87 -1,280.04
Long-Term Debt to NOPAT		 0.00 0.00 0.00
Altman Z-Score		 0.00 2.42 61.67
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00%
Liquidity Ratios		 - - -
Current Ratio		 0.00 0.68 1.89
Quick Ratio		 0.00 0.35 1.56
Cash Flow Metrics		 - - -
Free Cash Flow to Firm (FCFF)		 0.00 2.12 0.22
Operating Cash Flow to CapEx		 140.28% 148.12% -393.43%
Free Cash Flow to Firm to Interest Expense		 0.00 101.43 13.79
Operating Cash Flow to Interest Expense		 11.34 20.40 -76.96
Operating Cash Flow Less CapEx to Interest Expense		 3.26 6.63 -96.52
Efficiency Ratios		 - - -
Asset Turnover		 0.00 1.16 0.63
Accounts Receivable Turnover		 0.00 15.72 16.10
Inventory Turnover		 0.00 0.58 1.34
Fixed Asset Turnover		 0.00 12.44 8.69
Accounts Payable Turnover		 0.00 0.06 0.11
Days Sales Outstanding (DSO)		 0.00 23.23 22.68
Days Inventory Outstanding (DIO)		 0.00 630.46 271.62
Days Payable Outstanding (DPO)		 0.00 5,798.59 3,428.99
Cash Conversion Cycle (CCC)		 0.00 -5,144.91 -3,134.69
Capital & Investment Metrics		 - - -
Invested Capital		 0.00 -0.96 -1.17
Invested Capital Turnover		 0.00 -13.01 -4.52
Increase / (Decrease) in Invested Capital		 0.00 -0.96 -0.21
Enterprise Value (EV)		 0.00 5.39 468
Market Capitalization		 6.40 6.40 474
Book Value per Share		 $0.00 $0.00 $0.32
Tangible Book Value per Share		 $0.00 $0.00 $0.32
Total Capital		 0.00 0.36 5.37
Total Debt		 0.00 0.31 0.19
Total Long-Term Debt		 0.00 0.00 0.00
Net Debt		 0.00 -1.01 -6.35
Capital Expenditures (CapEx)		 0.21 0.29 0.31
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 0.00 -2.59 -2.51
Debt-free Net Working Capital (DFNWC)		 0.00 -1.27 4.03
Net Working Capital (NWC)		 0.00 -1.58 3.84
Net Nonoperating Expense (NNE)		 0.00 -0.04 0.03
Net Nonoperating Obligations (NNO)		 0.00 -1.01 -6.35
Total Depreciation and Amortization (D&A)		 0.39 0.26 0.22
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% -41.58% -52.17%
Debt-free Net Working Capital to Revenue		 0.00% -20.36% 83.79%
Net Working Capital to Revenue		 0.00% -25.41% 79.92%
Earnings Adjustments		 - - -
Adjusted Basic Earnings per Share		 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic Shares Outstanding		 0.00 0.00 16.15M
Adjusted Diluted Earnings per Share		 $0.00 $0.00 $0.00
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 0.00 16.15M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 0.00 17.18M
Normalized Net Operating Profit after Tax (NOPAT)		 0.83 1.16 -0.02
Normalized NOPAT Margin		 13.73% 18.65% -0.43%
Pre Tax Income Margin		 16.68% 23.07% 2.78%
Debt Service Ratios		 - - -
EBIT to Interest Expense		 38.77 66.68 4.85
NOPAT to Interest Expense		 31.71 55.59 0.31
EBIT Less CapEx to Interest Expense		 30.69 52.91 -14.71
NOPAT Less CapEx to Interest Expense		 23.63 41.82 -19.25
Payout Ratios		 - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for Charming Medical

No quarterly metrics and ratios for Charming Medical are available.


Financials Breakdown Chart

Charming Medical Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Charming Medical's financial year ends in March. Their financial year 2026 ended on March 31, 2026.

Charming Medical's net income appears to be on a downward trend, with a most recent value of -$22.65 thousand in 2026, falling from $821.74 thousand in 2024. The previous period was $1.20 million in 2025. View Charming Medical's forecast to see where analysts expect Charming Medical to go next.

Charming Medical's total operating income in 2026 was -$29.24 thousand, based on the following breakdown:
  • Total Gross Profit: $4.77 million
  • Total Operating Expenses: $4.80 million

Over the last 2 years, Charming Medical's total revenue changed from $6.02 million in 2024 to $4.81 million in 2026, a change of -20.1%.

Charming Medical's total liabilities were at $4.69 million at the end of 2026, a 11.7% decrease from 2025, and a 11.7% decrease since 2025.

In the past 1 years, Charming Medical's cash and equivalents has ranged from $816.77 thousand in 2025 to $4.70 million in 2026, and is currently $4.70 million as of their latest financial filing in 2026.

Over the last 2 years, Charming Medical's book value per share changed from 0.00 in 2024 to 0.32 in 2026, a change of 32.1%.


Related Companies

Financial statements for NASDAQ:MCTA last updated on 8/8/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel
Buy this stock today
Marc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...
Chaikin Analytics | Sponsoredtc pixel
Your book attached
Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...
Profits Run | Sponsoredtc pixel
SpaceX pays a 10X launch penalty
SpaceX burns roughly $200,000 in fuel per Falcon 9 launch - about $20 million across 100 missions. One unde...
Freedom Financial | Sponsoredtc pixel
Small Colorado Company (Backed by Sam Altman) Could Save U.S. Power Grid
A small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...
Altimetry | Sponsoredtc pixel
The Starlink of Energy
A portable energy unit - already used by the U.S. Navy for decades - is now drawing serious attention from Big...
Monument Traders Alliance | Sponsoredtc pixel
The REAL Reason Trump is Invading Iran
For a moment… Forget about Trump’s ties to Israel. Forget about reports of Iran’s nuclear program. Be...
Banyan Hill Publishing | Sponsoredtc pixel
$8B is moving in... are you?
Venture capital investment in US crypto companies hit $7.9 billion last year, up 44 percent from the year befo...
Awesomely | Sponsoredtc pixel